Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Apellis Pharmaceuticals Inc. shares valued at $82,500 were sold by Machiels Alec on Sep 15. At $66.00 per share, Machiels Alec sold 1,250 shares. The insider’s holdings dropped to 263,774 shares worth approximately $16.11 million following the completion of this transaction.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Also, Dunlop A. Sinclair sold 15,000 shares, netting a total of over 975,000 in proceeds. Following the sale of shares at $65.00 each, the insider now holds 240,679 shares.
Before that, Deschatelets Pascal had sold 12,000 shares from its account. In a trade valued at $767,760, the Chief Scientific Officer traded Apellis Pharmaceuticals Inc. shares for $63.98 each. Upon closing the transaction, the insider’s holdings decreased to 12,000 shares, worth approximately $58.08 million.
As published in their initiating research note from H.C. Wainwright on July 19, 2022, Apellis Pharmaceuticals Inc. [APLS] has been a Buy and the price target has been revised to $75. This represents a 18.55% premium over Thursday’s closing price. As of April 14, 2022, ROTH Capital has decreased its “Neutral” rating to a “Sell” for APLS. Earlier on December 08, 2021, Wells Fargo initiated its rating. Their recommendation was “an Overweight” for APLS stock.
Analyzing APLS’s Price Performance
On Thursday, Apellis Pharmaceuticals Inc. [NASDAQ: APLS] plunged -2.88% to $61.09. The stock’s lowest price that day was $59.78, but it reached a high of $62.29 in the same session. During the last five days, there has been a drop of approximately -5.65%. Over the course of the year, Apellis Pharmaceuticals Inc. shares have jumped approximately 29.21%. Shares of the company reached a 52-week high of $70.00 on 09/09/22 and a 52-week low of $33.32 on 05/11/22. A 50-day SMA is recorded $60.59, while a 200-day SMA reached $48.97. Nevertheless, trading volume fell to 1.03 million shares from 0.94 million shares the previous day.
Support And Resistance Levels for Apellis Pharmaceuticals Inc. (APLS)
According to the 24-hour chart, there is a support level at 59.82, which, if violated, would cause prices to drop to 58.54. In the upper region, resistance lies at 62.33. The next price resistance is at 63.56. RSI (Relative Strength Index) is 46.56 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -1.68, which suggests the price will decrease in the coming days. Percent R is at 70.43%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
Is Apellis Pharmaceuticals Inc. subject to short interest?
Stocks of Apellis Pharmaceuticals Inc. saw a sharp rise in short interest on Jul 14, 2022 jumping by 0.22 million shares to 9.37 million. Data from Yahoo Finance shows that the short interest on Jun 14, 2022 was 9.15 million shares. A jump of 2.35% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 9.86 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.86.
Which companies own the most shares of Apellis Pharmaceuticals Inc. (APLS)?
According to Wellington Management Co. LLP filings, the company currently owns 11,542,743 shares, which is about 10.51% of the total APLS shares outstanding. The investor’s shares have plunged by -2,656,551 from its previous 13-F filing of 14199294.0 shares. With the completion of the buy transaction, Avoro Capital Advisor LLC’s stake is now worth $593,300,550. T. Rowe Price Associates, Inc. acquire a 10.08% interest valued at $525.22 million while The Vanguard Group, Inc. purchased a 139,206 stake. A total of 738,030 shares of Apellis Pharmaceuticals Inc. were bought by BlackRock Fund Advisors during the quarter, and 0 by Ecor1 Capital LLC. In its current portfolio, SSgA Funds Management, Inc. holds 3,496,925 shares valued at $211.6 million.
In terms of Apellis Pharmaceuticals Inc. share price expectations, FactSet research, analysts set an average price target of $77.82 in the next 12 months, up nearly 27.19% from the previous closing price of $62.90. Analysts anticipate Apellis Pharmaceuticals Inc. stock to reach $113.00 by 2022, with the lowest price target being $40.00. In spite of this, 17 analysts ranked Apellis Pharmaceuticals Inc. stock as an Overweight at the end of 2022. On November 29, 2021, ROTH Capital assigned a price target of “a Neutral” to the stock and downgraded coverage with a $40.